Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Equity Average (2021 - 2025)

Historic Equity Average for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $170.0 million.

  • ARS Pharmaceuticals' Equity Average fell 1831.8% to $170.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.0 million, marking a year-over-year decrease of 1831.8%. This contributed to the annual value of $243.8 million for FY2024, which is 319.43% down from last year.
  • ARS Pharmaceuticals' Equity Average amounted to $170.0 million in Q3 2025, which was down 1831.8% from $210.6 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Equity Average's 5-year high stood at $359.1 million during Q2 2021, with a 5-year trough of $131.0 million in Q1 2022.
  • Its 5-year average for Equity Average is $239.8 million, with a median of $238.5 million in 2023.
  • In the last 5 years, ARS Pharmaceuticals' Equity Average plummeted by 2035.34% in 2022 and then skyrocketed by 10386.28% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Equity Average (Quarter) stood at $150.4 million in 2021, then surged by 79.47% to $270.0 million in 2022, then fell by 13.32% to $234.0 million in 2023, then fell by 2.19% to $228.9 million in 2024, then dropped by 25.73% to $170.0 million in 2025.
  • Its last three reported values are $170.0 million in Q3 2025, $210.6 million for Q2 2025, and $242.9 million during Q1 2025.